IMPRiND Consortium launched March 2017

IMPRiND Consortium launched March 2017

On 1 March 2017 the Innovative Medicines Initiative (IMI) launched IMPRiND, an innovative research project that is devoted to investigate whether mechanisms of propagation of aggregated proteins between cells could enable novel therapeutic approaches in Alzheimer's and Parkinson's diseases.

Alzheimer's and Parkinson's diseases are age-related neurodegenerative disorders without cure. They are characterized by the progressive loss of brain cells often along interconnected networks. Recent evidence suggests that this progressive march of pathological lesions may be due to the release and uptake of specific aggregated proteins which act as templates for further aggregation once inside cells.

However, a complete understanding of such events and the underpinning cellular mechanisms is still lacking. IMPRiND aims to fill this knowledge gap and develop tools and assays for targeting these pathways to pave the way for novel therapeutics that could delay the progression of Alzheimer's and Parkinson's disease.

Dr. George Tofaris of the University of Oxford and IMPRiND project coordinator, commented: "We are seeking to understand how aggregated proteins are handled once inside brain cells and how they are passaged from cell to cell. To this end, we will work collaboratively to develop standardized tools and assays to establish disease-relevant mechanisms that could enable future therapies against disease progression in this area of unmet need".

The Centre's Associate Director Dr. Susanna-Assunta Sansone, who co-coordinates the data management activities for the IMPRiND project, adds, "We will implement methods and standards-driven tools to improve the collection, curation, representation and publication of multi-dimensional data to be produced. Ultimately we will ensure that that data and all other research outputs are Findable, Accessible, Interoperable and Reusable, according to the FAIR principles".

IMPRiND has a total budget of 11.4 million Euros. It is supported by the IMI with 4.7 million Euros, by industrial partners with 6.4 million Euros and 0.3 million Euros from the Swiss Federation. The project runs over four years and will end on 31 February 2021. The consortium brings together pharmaceutical companies and public research organisations from across Europe.

In Alzheimer's disease, affected patients suffer from a progressive loss of memory whereas in Parkinson's disease the most prominent symptoms relate to slowness of movement as well as memory decline in a proportion of them. Today, over 45 million people worldwide live with dementia and up to 10 million with Parkinson's disease. It is estimated that the number of patients with neurodegenerative brain diseases will increase to 131.5 million by 2050 (World Alzheimer Report 2015).